Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT 3 receptor antagonists and dexamethasone.

Int J Clin OncolJul 21, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Takeshi Aoyama, Hirotoshi Iihara, Masakazu Abe et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the comparative effectiveness of 5-HT3 receptor antagonists versus dexamethasone for preventing chemotherapy-induced nausea and vomiting in adult patients receiving low-emetogenic chemotherapy. The review found no direct comparative evidence from randomized controlled trials or observational studies, highlighting a significant gap in the literature.

Key findings

  • No direct comparative evidence was found between 5-HT3 receptor antagonists and dexamethasone for low-emetogenic chemotherapy.
  • The review screened 430 articles, ultimately including no studies that met the inclusion criteria.
  • Future research should focus on prospective comparative trials and real-world data analyses.

Why it matters

Understanding the effectiveness of antiemetic therapies is crucial for improving patient quality of life during chemotherapy. This review underscores the need for robust evidence to guide clinical practice in managing chemotherapy-induced nausea and vomiting.

Source

PubMed · PMID 42479257Free full text on PubMed Central

Published in Int J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.